Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 17, 2023 (3 years ago)

ePHEDrine in 0.9% sodium chloride

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1

Affected NDC 71286-6004-01

Compare with the code on your package — it is the most precise check available.

Drug: Ephedrine

Recalling firm
Central Admixture Pharmacy Services Inc
NDC code
71286-6004-1
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1073-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ephedrine recalls

See all
Class II · Moderate risk

Ephedrine Plus

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation NDC 65193-320-24 D-0473-2022

Other recalls by Central Admixture Pharmacy Services Inc

All 2023 recalls